1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Cures Within Reach Funding Opportunity (Clinical Repurposing Research to Impact US Veterans/Military) is sponsored by Cures Within Reach. This Request for Proposals (RFP) supports clinical trials that repurpose approved drugs, devices, nutraceuticals, and/or diagnostics, as well as combination therapies to address unmet and high-priority medical needs of US veterans/military, including mental health, PTSD, and bra…
Get alerted about grants like this
Get emailed when new opportunities from “Cures Within Reach” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
If you don’t have a ProposalCentral login , visit ProposalCentral here, then click on “Need an Account” found in the bottom right.
Clinical Trials to Validate AI-Driven Drug Repurposing : accepting submissions of investigator-initiated, proof of concept, Phase I or Phase IIA clinical trials to validate artificial intelligence (AI)-driven repurposing opportunities in any unsolved disease, where the therapies supported by AI models are already approved.
Eligible clinical repurposing trials must include AI-generated data as part of the preclinical support for the trial. Budget: up to $100,000, including a 10% institutional match, with additional funds available for community engagement. LOI deadline closed; submissions under review.
Any unsolved disease is eligible, although there is a preference for rare diseases. Both on- and off-patent drugs and biologics are eligible, although there is a preference for off-patent. Data from any AI model is eligible, although there is a preference for openly accessible models and for models developed by nonprofits/government.
The document “ Potential AI Model Resources for CWR 2026 RFP ” is solely available to provide options to prospective clinical researchers and has been developed as just one resource of potential AI models that could be used as part of an RFP submission. The data in “ Potential AI Model Resources for CWR 2026 RFP ” is provided by AI models, not CWR.
This is not meant to be an exhaustive list of eligible AI models, and models not included in this list may be eligible for AI validation submissions. This downloadable file will be updated by CWR during the Letter of Intent (LOI) submission window, so be sure to utilize the most recent version. If you have an AI model to include in this list, email Admin@CuresWithinReach.
org for details. Clinical Repurposing Research to Impact Veterans/Military 2026 : accepting budgets of up to $75,000 from U.S.-based institutions for clinical repurposing trials in any disease area impacting veterans or active military, such as mental health, PTSD and brain injuries. LOI deadline closed; submissions under review.
Repurposing Research for Chicago 2026 : accepting budgets of up to $125,000 for clinical repurposing trials from Chicago area research institutions in one or both of the tracks listed below. LOI deadline closed; submissions under review. Track 1 – Investigator Groups : clinical repurposing trials in any unsolved disease led by an Early Stage Investigator or an underrepresented researcher.
Track 2 – Patient Groups : clinical repurposing trials impacting specific patient groups, such as health disparities, pediatrics, rare diseases and/or veterans issues (including mental health, PTSD and brain injuries).
ReGRoW: Funding for Underresourced Researchers in Low and Lower-Middle Income Countries 2026 : accepting budgets of up to $70,000 for clinical repurposing trials in any disease led by an underresourced researcher in any LMIC, as defined by the World Bank . LOI deadline closed; submissions under review. If you don’t have a ProposalCentral login , visit ProposalCentral here, then click on “Need an Account” found in the bottom right.
Watch this short video below for LOI Submission Process and Tips ↙️ Learn More About What Stages of Research CWR Funds ↙️ click photo above to enlarge Become a CWR Grant Review Committee Member Clinical Trials to Validate AI-Driven Drug Repurposing : now accepting submissions of investigator-initiated, proof of concept, Phase I or Phase IIA clinical trials to validate artificial intelligence (AI)-driven repurposing opportunities in any unsolved disease, where the therapies supported by AI models are already approved.
Eligible clinical repurposing trials must include AI-generated data as part of the preclinical support for the trial. Budget: up to $100,000, including a 10% institutional match, with additional funds available for community engagement. Any unsolved disease is eligible, although there is a preference for rare diseases.
Both on- and off-patent drugs and biologics are eligible, although there is a preference for off-patent. Data from any AI model is eligible, although there is a preference for openly accessible models and for models developed by nonprofits/government.
The document “ Potential AI Model Resources for CWR ” is solely available to provide options to prospective clinical researchers and has been developed as just one resource of potential AI models that could be used as part of an RFP submission. The data in “ Potential AI Model Resources for CWR ” is provided by AI models, not CWR.
This is not meant to be an exhaustive list of eligible AI models, and models not included in this list may be eligible for AI validation submissions. This downloadable file will be updated by CWR during the Letter of Intent (LOI) submission window, so be sure to utilize the most recent version. If you have an AI model to include in this list, email Sydney@CuresWithinReach.
org for details.
Repurposing Research to Improve Patient Outcomes in Meniere’s Disease and Related Diagnoses: Clinical and Preclinical Projects : for clinical repurposing trials (budgets up to $350,000) and preclinical repurposing research (budgets up to $100,000) in Meniere’s disease as well as other vertigo and hearing loss-related diagnoses, including benign paroxysmal positional vertigo (BPPV), tinnitus, labyrinthitis and vestibular neuritis.
ReGRoW: Funding for Underresourced Researchers in Low and Lower-Middle Income Countries 2025 : accepting budgets of up to $65,000 for clinical repurposing trials in any disease led by an underresourced researcher in any LMIC, as defined by the World Bank .
Repurposing Research for Chicago 2025 : accepting budgets of up to $100,000 for clinical repurposing trials from Chicago area research institutions in one or more of the tracks listed below. Track 1 – Health Equity : clinical repurposing trials that 1) address health disparities, including women’s health, among underrepresented patients OR 2) are led by an underrepresented researcher OR both 1) and 2).
Track 2 – Early Stage Investigators : clinical repurposing trials in any unsolved disease led by a researcher who is within 10 years of completing an advanced degree or medical residency. Track 3 – Pediatrics : clinical repurposing trials to address unmet medical needs of pediatric patients, including adding a pediatric arm to an adult clinical repurposing trial.
Track 4 – Veterans/Military : clinical repurposing trials to address unmet medical needs of US veterans and/or active US military, including but not limited to mental health, PTSD and brain injuries.
US Based Repurposing Clinical Trials to Address Health Equity 2024: INVITE ONLY accepting budgets of up to $75,000 for repurposing clinical trials to address health equity, including repurposing clinical trials that EITHER are 1) led by an underrepresented researcher OR 2) address health disparities among underrepresented patients OR 3) both 1) and 2).
Impacting Blood Cancers through Clinical Repurposing Trials 2024 : accepting budgets of up to $75,000 from institutions worldwide for clinical repurposing trials targeting any blood cancer, with a preference for trials impacting multiple myeloma and/or myelodysplastic syndromes.
ReGRoW: Funding for Underresourced Researchers in Low and Lower-Middle Income Countries 2024 : accepting budgets of up to $65,000 for clinical repurposing trials in any disease led by an underresourced researcher in any LMIC, as defined by the World Bank .
Clinical Repurposing Research to Impact Veterans/Military 2024 : accepting budgets of up to $75,000 to a U.S.-based institution for a repurposing clinical trial in any disease area impacting veterans or active military, such as mental health, PTSD and brain injuries.
Repurposing Research for Chicago 2024 : accepting budgets of up to $100,000 for clinical repurposing trials from Chicago area research institutions in one or more of the following tracks.
Track 1 – Diversity, Equity and Inclusion : clinical repurposing trials that 1) are led by an underrepresented researcher ( as defined by the NIH ) OR 2) address health disparities among underrepresented patients ( as defined by the NIH ) OR both 1) and 2).
Track 2 – Early Stage Investigators : clinical repurposing trials in any unsolved disease led by a researcher who is within 10 years of completing an advanced degree or medical residency. Track 3 – Pediatrics : clinical repurposing trials to address unmet medical needs of pediatric patients, including adding a pediatric arm to an adult clinical repurposing trial.
Track 4 – Veterans/Military : clinical repurposing trials to address unmet medical needs of US veterans and/or active US military, including but not limited to mental health, post-traumatic stress disorder (PTSD) and brain injuries.
ReGRoW: Repurposing Grants for the Rest of the World – Funding for Underserved Researchers in Low and Lower-Middle Income Countries (LMICs) : for clinical repurposing trials in any disease led by an underserved researcher in any LMIC, as defined by the World Bank – accepting budgets of up to $60,000 US Based Clinical Repurposing Trials to Address Diversity, Equity and Inclusion (DEI) : for clinical repurposing trials in any disease from US research institutions testing any repurposed therapy and that support the US-based Cures Within Reach DEI efforts for underrepresented patients and researchers – accepting budgets of up to $75,000 Repurposing Research to Address Diversity, Equity and Inclusion in the Greater Chicago Area : for clinical repurposing trials from Chicagoland research institutions testing any repurposed therapy and that support the US-based Cures Within Reach DEI efforts for underrepresented patients and researchers – accepting budgets of up to $100,000 Clinical Repurposing Research to Impact Veterans/Military: INVITE ONLY for repurposing clinical trials in any disease area impacting veterans, including mental health, PTSD and brain injuries – up to $75,000 Repurposing Research to Improve Patient Outcomes in Meniere’s Disease and Related Diagnoses: Clinical and Preclinical Projects : for clinical repurposing trials (budgets up to $100,000) and preclinical repurposing research (budgets up to $50,000) in Meniere’s disease as well as other vertigo and hearing loss-related diagnoses, including benign paroxysmal positional vertigo (BPPV), tinnitus, labyrinthitis and vestibular neuritis Drug Repurposing Clinical Trials to Impact Blood Cancers : for clinical repurposing trials testing repurposed drugs in any blood cancer from anywhere in the world – accepting budgets of up to $75,000.
Repurposing Research to Address Diversity , Equity and Inclusion (DEI) in the Greater Chicago Area : for clinical repurposing trials from Chicagoland research institutions testing any repurposed therapy and that support the US-based Cures Within Reach DEI efforts for underrepresented racial / ethnic minority patients and researchers – accepting budgets of up to $100,000.
US Based Clinical Repurposing Trials to Address Diversity, Equity and Inclusion (DEI) : for clinical repurposing trials in any disease from US research institutions testing any repurposed therapy and that support the US-based Cures Within Reach DEI efforts for underrepresented racial / ethnic minority patients and researchers – accepting budgets of up to $70,000. CureAccelerator Live!
for Diversity, Equity and Inclusion (DEI) in Rare Diseases : for clinical repurposing trials in any rare disease from US research institutions testing any repurposed therapy and that support the US-based Cures Within Reach DEI efforts for underrepresented racial / ethnic minority patients and researchers – accepting budgets of up to $70,000.
ReGRoW: Repurposing Grants for the Rest of the World – Funding for Underserved Researchers in Low and Lower-Middle Income Countries (LMICs) : for clinical repurposing trials in any disease led by an underserved researcher in any LMIC, as defined by the World Bank – accepting budgets of up to $50,000.
Clinical Repurposing Research to Impact Veterans : repurposing clinical trials in any disease area impacting veterans, including mental health, PTSD and brain injuries – up to $50,000 CureAccelerator Live!
for Pediatric Rare Diseases : repurposing clinical trials in any pediatric rare disease – up to $50,000 Repurposing Research to Improve Clinical Patient Outcomes in Meniere’s Disease and Related Symptoms / Consequences : repurposing clinical trials to address Meniere’s disease and symptoms / consequences of Meniere’s disease, including tinnitus and hearing loss – up to $100,000 Preclinical Repurposing Research to Address Meniere’s Disease and Related Symptoms / Consequences : repurposing preclinical project to address Meniere’s disease and symptoms / consequences of Meniere’s disease, including tinnitus and hearing loss – up to $50,000 Repurposing Research Led by a US-Based Racial / Ethnic Minority Principal Investigator : clinical repurposing trials in any disease led by a US-based racial / ethnic minority PI underrepresented in biomedical research, as defined by the NIH – up to $70,000 Repurposing Research to Address Racial / Ethnic Health Disparities in the Greater Chicago Area : clinical repurposing trials from any research institution in the greater Chicago area to address racial / ethnic health disparities in communities of color as defined by the NIH – up to $80,000 ReGRoW: Repurposing Grants for the Rest of the World – Funding for Underserved Researchers in Low and Lower-Middle Income Countries (LMICs) : clinical repurposing trials led by an underserved researcher in any LMIC, as defined by the World Bank – up to $50,000 ReGRoW Pilot: clinical repurposing research projects from PIs based in low and lower-middle income countries (LMICs) to find treatments for patients in LMICs Rare Blood Cancers and Retinitis Pigmentosa : clinical repurposing research projects – up to $50,000 Meniere’s Disease: clinical repurposing research projects – up to $100,000 Meniere’s Disease: pre-clinical repurposing research projects – up to $50,000 Canine-Focused Comparative Trials : repurposing research projects from PIs based in North America and Europe – up to $25,000 Chicagoland Clinical Repurposing Trials: repurposing research projects from PIs based in the Chicago area – up to $50,000 Questions?
Contact Clare Thibodeaux, PhD, Vice President, Scientific Affairs at clare@cureswithinreach. org
According to the current listing, eligibility includes: Researchers focusing on clinical repurposing research for US veterans/military. Confirm the full requirements in the official notice before applying.
Cures Within Reach Funding Opportunity (Clinical Repurposing Research to Impact US Veterans/Military) is funded by Cures Within Reach. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward interdisciplinary projects that leverage AI, machine learning, and advanced data science to address pressing questions in biomedical and public health research. It seeks to advance fundamental scientific and engineering contributions across disciplines to solve key health problems.
HRSA-26-078 splits $9.1 million among roughly 10 Public Health Training Centers, with awards up to $910,000 and applications due July 17, 2026. Eligibility runs to accredited schools of public health and other nonprofit training institutions. Here's why the winning applications are the ones that can prove an existing, mapped relationship with state and local health departments — not the ones promising the slickest coursework.
Read articleThe Department of Education's May 19 final rule activates Workforce Pell on July 1, 2026, opening federal aid to short-term training programs as brief as 8 weeks. Governors and state workforce boards — not accreditors — pick the eligible industries, and only programs that pass earnings-vs-cost gates make the list.
Read articleA new executive order, a DOJ National Fraud Enforcement Division, and a multi-agency task force are creating the most powerful federal grant enforcement apparatus in decades. What every recipient needs to understand.
Read article